Bal Pharma Ltd
NSE:BALPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (6.9), the stock would be worth ₹81.62 (7% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.4 | ₹76.16 |
0%
|
| 3-Year Average | 6.9 | ₹81.62 |
+7%
|
| 5-Year Average | 6.4 | ₹75.52 |
-1%
|
| Industry Average | 29.2 | ₹346.8 |
+355%
|
| Country Average | 23 | ₹272.99 |
+258%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
B
|
Bal Pharma Ltd
NSE:BALPHARMA
|
1.2B INR | 6.4 | 14.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 49.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 19.6 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 14.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 16.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.9 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 12.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 8.3 | 16.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Bal Pharma Ltd
Glance View
Bal Pharma Ltd. is a holding company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The firm is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The firm specializes in prescription drugs, generic, over the counter (OTC) products, intravenous infusion and bulk actives. The company offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, and diuretic, acne treatment. The company also manufactures and supplies natural medicines in the segment of bulk actives, formulations, generics and herbals. Its finished formulation products covers dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments. The firm offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.
